An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
OpGen, Inc. (Nasdaq: OPGN) received a notice from Nasdaq regarding the delayed filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company previously faced non-compliance issues with the Minimum Bid Price Rule. OpGen has until June 3, 2024, to regain compliance with the Minimum Bid Price Rule and file the Form 10-K to avoid delisting.
OpGen, Inc. (Nasdaq: OPGN) ha ricevuto una notifica da Nasdaq riguardante il ritardo nella presentazione del suo Rapporto Annuale su Modulo 10-K per l'anno fiscale conclusosi il 31 dicembre 2023. In precedenza, l'azienda aveva già affrontato problemi di non conformità con la Regola del Prezzo Minimo di Offerta. OpGen ha tempo fino al 3 giugno 2024 per rientrare in conformità con la Regola del Prezzo Minimo di Offerta e presentare il Modulo 10-K per evitare la cancellazione dalla lista.
OpGen, Inc. (Nasdaq: OPGN) recibió una notificación de Nasdaq sobre el retraso en la presentación de su Informe Anual en el Formulario 10-K para el año fiscal que finalizó el 31 de diciembre de 2023. Anteriormente, la compañía enfrentó problemas de incumplimiento con la Regla de Precio Mínimo de Oferta. OpGen tiene hasta el 3 de junio de 2024 para cumplir con la Regla de Precio Mínimo de Oferta y presentar el Formulario 10-K para evitar ser excluida de la lista.
OpGen, Inc. (나스닥: OPGN)은 2023년 12월 31일에 종료된 회계연도에 대한 연차 보고서(Form 10-K) 제출 지연과 관련하여 나스닥으로부터 통지를 받았습니다. 회사는 이전에 최소 입찰 가격 규칙에 따른 비준수 문제를 겪었습니다. OpGen은 주식 상장 폐지를 피하기 위해 2024년 6월 3일까지 최소 입찰 가격 규칙을 준수하고 Form 10-K를 제출해야 합니다.
OpGen, Inc. (Nasdaq: OPGN) a reçu un avis de Nasdaq concernant le retard dans le dépôt de son rapport annuel sur formulaire 10-K pour l'exercice clos le 31 décembre 2023. La société avait précédemment fait face à des problèmes de non-conformité avec la Règle du Prix d'Offre Minimum. OpGen a jusqu'au 3 juin 2024 pour se conformer à la Règle du Prix d'Offre Minimum et déposer le formulaire 10-K afin d'éviter un retrait de cotation.
OpGen, Inc. (Nasdaq: OPGN) erhielt eine Benachrichtigung von Nasdaq über die verzögerte Einreichung seines Jahresberichts auf Formular 10-K für das am 31. Dezember 2023 endende Geschäftsjahr. Das Unternehmen hatte zuvor Probleme mit der Einhaltung der Regel zum Mindestgebotspreis. OpGen hat bis zum 3. Juni 2024 Zeit, die Regel zum Mindestgebotspreis zu erfüllen und das Formular 10-K einzureichen, um eine Delistung zu vermeiden.
Positive
None.
Negative
OpGen's delay in filing the Form 10-K could lead to a delisting determination by Nasdaq if not resolved by June 3, 2024.
ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”). The Company previously filed a Form 12b-25 with the SEC disclosing that it was unable to file the Form 10-K by April 1, 2024 without unreasonable effort or expense.
The Company previously received written notices from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) for failing to maintain a minimum bid price of $1.00 per share for a 30 consecutive business day period (the “Minimum Bid Price Rule”). As previously disclosed, on February 9, 2024, the Company received written notice from Nasdaq that a Nasdaq Hearings Panel had granted the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule. The most recent notice provides that the Nasdaq Hearings Panel will consider the delinquent Form 10-K in connection with its prior grant of an additional period to regain compliance. If the Nasdaq Hearings Panel continues to permit the Company the additional period to regain compliance, the Company expects that it will be required by Nasdaq to file the Form 10-K no later than June 3, 2024 to avoid a delisting determination.
The notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. While the Company can provide no assurance as to timing, the Company is working diligently to finalize the Form 10-K and plans to file the Form 10-K as soon as practicable to regain compliance with the Nasdaq Listing Rule.
About OpGen, Inc. OpGen, Inc. (Rockville, Md., U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. The Company distributes molecular microbiology solutions that help guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.
This press release includes statements regarding a notice of non-compliance received from Nasdaq. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to timely complete our financial reporting processes with the Company’s auditors and file the Form 10-K, the impacts of other unanticipated delays to the Company’s financial reporting process or other violations of Nasdaq Listing Rules, our ability to regain compliance with Nasdaq Listing Rules, our ability to continue to finance our business and operations, and our liquidity and working capital requirements. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
opgen, inc. (nasdaq: opgn) is harnessing the power of informatics and genomic analysis to provide complete solutions for infection prevention and treatment. using our large and ever-growing acuitas lighthouse® knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases. today, through our clia-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. our fda-cleared, ivd products rapidly identify pathogens in positive blood cultures.
